Method of treating conditions related to the PGI2 receptor

ABSTRACT

Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chloropbenyl)(pbenyl)carbamoyloxy)methyl)cyclohexyi)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

This application is a division of Ser. No. 16/870,777, filed May 8,2020, which is a division of Ser. No. 16/706,424, filed Dec. 6, 2019,now U.S. Pat. No. 10,688,076, issued Jun. 23, 2020, which is a divisionof U.S. patent application Ser. No. 15/520,864, filed Apr. 21, 2017, nowU.S. Pat. No. 10,537,546, issued Jan. 21, 2020, which is a U.S. NationalStage entry of International Application No. PCT/US2015/056824, filedOct. 22, 2015, which claims the benefit of priority from U.S.Provisional Patent Application No. 62/067,916, filed Oct. 23, 2014, allof which are hereby incorporated by reference in their entirety.

Provided are methods useful in the treatment of: pulmonary arterialhypertension (PAH); idiopathic PAH; familial PAH; PAH associated with: acollagen vascular disease, a congenital heart disease, portalhypertension, HIV infection, ingestion of a drug or toxin, hereditaryhemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusivedisease (PVOD) or pulmonary capillary hemangiomatosis (PCH); and PAHwith significant venous or capillary involvement.

Prostacyclin (PGI2) is a lipid molecule derived from arachidonic addthrough the cyclooxygenase pathway. It is a potent vasodilator,antiproliferative, anti-thrombotic and antiplatelet agent that mediatesits effects as an agonist of a G protein-coupled receptor (PGI2receptor; e.g., human PGI2 receptor, GenBank® Accession No. NP 000951and alleles thereof). It is known that the binding of PGI2 (or othersuch agonist) to the PGI2 receptor leads to coupling with the Gs proteinand increases intracellular cAMP levels. (See, e.g., Zhang et al, Arch.Biochem. Biophys., 2006, 454:80-88.)

Pulmonary arterial hypertension (PAH) is a life-threatening diseasecharacterized by a progressive pulmonary vasculopathy leading to rightventricular hypertrophy. Right heart failure occurs if left untreated.Prostacyclin, which has vasodilatory and antiproliferative effects onthe pulmonary vasculature has been found to be low in patients with PAHcompared with normal controls. Exogenous administration of prostacyclinor an analog of prostacyclin {i.e., an agonist of the PGI2 receptor) hasbecome an important strategy in the treatment of PAH. (See, e.g., Tuderet al, Am. J. Respir. Cut. Care. Med., 1999, 159: 1925-1932; Humbert etal, J. Am. Coll. Cardiol, 2004, 43:13S-24S; Rosenzweig, Expert Opin.Emerging Drugs, 2006, 11:609-619; McLaughlin et al, Circulation, 2006,114:1417-1431; Rosenkranz, Clin. Res. Cardiol, 2007, 96:527-541;Driscoll et al, Expert Opin. Pharmacother., 2008, 9:65-81.)

Trepostinil and iloprost are FDA-approved analogs of prostacyclin which,like prostacyclin, are not orally-active. Beraprost is an orally-activeanalog of prostacyclin approved for the treatment of PAH in Japan, butit has failed registration for the treatment of PAH in Europe and in theUS. Of the three FDA-approved drugs, prostacyclin is the best studied inPAH patients. The approximate annual cost of treating PAH with thesedrugs is $25,000 to $200,000 depending on the dose. At present, manyexperts consider intravenous prostacyclin to be the most reliable agentfor managing the sickest PAH patients. Due to the short half-life ofprostacyclin, intravenous treatment is complicated by the need for acontinuous infusion. Patients are at risk for potentially fatal reboundpulmonary hypertension if the infusion is abruptly disrupted, as well assignificant risk of catheter-related complications including sepsis.(See, e.g., Rosenzweig, Expert Opin. Emerging Drugs, 2006, 11:609-619;Naeije et ai, Expert Opin. Pharmacother., 2007, 8:2247-2265; Strauss etai, Clin. Chest. Med., 2007, 28:127-142; Driscoll et ai, Expert Opin.Pharmacother., 2008, 9:65-81.)

2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy(acetic acid (Compound 1), also known as APD811, an orally availableagonist of the prostacyclin (IP) receptor, is disclosed in U.S. PatentPublication. No. 2011/0053958, incorporated by reference herein in itsentirety. Compound 1 is an investigational drug candidate intended forthe treatment of vasospastic diseases, such as Pulmonary ArterialHypertension.

There exists a need for effectively treating patients who are in need oftreatment with Compound 1. The present disclosure satisfies this needand provides related advantages as well.

SUMMARY

Provided is a method of treating pulmonary arterial hypertensioncomprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a pharmaceutically acceptable salt, hydrate, or        solvate thereof,    -   wherein Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, is administered via a titration        scheme that comprises the up-titration of Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        over a period of no more than about nine weeks until an        optimized dose is administered.

Also provided is a method of determining an optimized dose for a patientin need of treatment of pulmonary arterial hypertension, comprising

-   -   prescribing and/or administering to the patient Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        and    -   increasing the dose of Compound 1, or a pharmaceutically        acceptable salt, hydrate, or solvate thereof, over a period of        no more than about nine weeks, until the optimized dose for the        patient is administered.

Also provided is a method of determining an optimized dose for a patientin need of treatment with Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, comprising:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        to the patient at an initial dose equivalent to 0.01 mg of        Compound 1 once daily for about one week; and    -   determining whether the patient tolerates the initial dose;        wherein if the patient tolerates the initial dose, the dose is        increased to a dose equivalent to 0.01 mg of Compound 1 twice        daily;        wherein if the patient does not tolerate the initial dose, the        optimized dose for the patient is less than a dose equivalent to        0.01 mg of Compound 1 once daily.

In some embodiments, the method of determining the optimized dose forthe patient in need thereof further comprises:

-   -   determining whether the patient tolerates the dose equivalent to        0.01 mg of Compound 1 twice daily;    -   wherein if the patient tolerates the dose equivalent to 0.01 mg        of Compound 1 twice daily, the dose is increased by an amount        equal to a first incremental value;    -   wherein if the patient does not tolerate the dose equivalent to        0.01 mg of Compound 1 twice daily, the optimized dose for the        patient is a dose equivalent to 0.01 mg of Compound 1 once        daily.

In some embodiments, the method of determining the optimized dose forthe patient in need thereof further comprises:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        to the patient at the increased dose for about one week; and    -   determining whether the patient tolerates the increased dose;    -   wherein if the patient tolerates the increased dose, the dose is        further increased by an amount equal to a second incremental        value, wherein the second incremental value is the same or        different from the first incremental value;    -   wherein if the patient does not tolerate the increased dose, the        optimized dose for the patient is equal to the difference        between the increased dose and the first incremental value.

Also provided is a method of determining an optimized dose for a patientin need of treatment with Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, comprising:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        to the patient at an initial dose equivalent to 0.01 mg of        Compound 1 twice daily for about one week;    -   determining whether the patient tolerates the initial dose; and    -   wherein if the patient tolerates the initial dose, the dose is        increased by an amount equal to a first incremental value;    -   wherein if the patient does not tolerate the initial dose, the        optimized dose for the patient is less than a dose equivalent to        0.01 mg of Compound 1 twice daily.

In some embodiments, the method of determining the optimized dose forthe patient in need thereof further comprises:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        to the patient at the increased dose for about one week; and    -   determining whether the patient tolerates the increased dose;    -   wherein if the patient tolerates the increased dose, the dose is        further increased by an amount equal to a second incremental        value, wherein the second incremental value is the same or        different from the first incremental value;    -   wherein if the patient does not tolerate the increased dose, the        optimized dose for the patient is equal to the difference        between the increased dose and the first incremental value.

Also provided is a method of determining an optimized dose for a patientin need of treatment with Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, comprising a cycle of:

-   -   prescribing and/or administering to the patient the increased        dose for a period of about one week;    -   further increasing the dose by an amount equal to an incremental        value; and    -   determining whether the patient tolerates the further increased        dose;    -   wherein the cycle is repeated so long as the patient tolerates        the further increased dose, wherein the incremental value at        each cycle repetition is the same or different; and    -   wherein if the patient does not tolerate the further increased        dose, the optimized dose for the patient is equal to the        difference between the further increased dose and the        incremental value for the last cycle repetition.

Also provided is a titration package for enabling compliance with aregimen of changing dosage of medication over a period of time, whereinthe medication is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, the package comprising:

-   -   a backing having an array of receivers, said array including a        plurality of columns and a plurality of rows;    -   a plurality of sets of solid dosage forms, each solid dosage        form in a set having a common dose of the medication and a        different dose than a solid dosage form of a different set, each        set being disposed in receivers of one of an adjacent row and an        adjacent column; different sets of solid dosage forms are        disposed in different rows, each row being indicated as a        successive time period, each column being indicated as a        different day of the time period, sets of solid dosage forms        having increased doses being disposed in receivers of rows        indicated as successive time periods; and indicia disposed        adjacent the columns and rows for displaying common days and        successive time periods.

Also provided is a kit comprising a titration package as disclosedherein and instructions indicating that the medication is to beadministered to a patient in need of treatment of pulmonary arterialhypertension.

Also provided is a method of treating pulmonary arterial hypertensioncomprising providing a titration package as disclosed herein to patientin need thereof.

Also provided is a method of determining an optimized dose for a patientin need of treatment of pulmonary arterial hypertension, comprising

-   -   prescribing and/or administering to the patient Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        and    -   increasing the dose of Compound 1, or a pharmaceutically        acceptable salt, hydrate, or solvate thereof, over a period of        no more than about nine weeks.

DETAILED DESCRIPTION

As used in the present specification, the following words and phrasesare generally intended to have the meanings as set forth below, exceptto the extent that the context in which they are used indicatesotherwise.

COMPOUND 1: As used herein, “Compound 1” refers to2-(((1r,4r)-4-(((4-ehlorophenyiXphenyl)carbamoyloxy)methyl)eyclohexyl)methoxy)aeeticacid including crystalline forms thereof. As a non-limiting example,Compound 1 may be present in the crystalline form disclosed inWO2009117095 (incorporated by reference herein in its entirety), whichmay be characterized by one or more of the following °2Θ values for thepeaks in the PXRD spectrum: 8.9, 10.8, 11.9, 15.2, 16.4, 16.8, 18.9,20.3, 207 and 21.5, wherein the reported peaks can vary by about±0.2°2Θ.

ADMINISTERING: As used herein, “administering” means to provide acompound or other therapy, remedy or treatment. For example, a healthcare practitioner can directly provide a compound to a patient in theform of a sample, or can indirectly provide a compound to a patient byproviding an oral or written prescription for the compound. Also, forexample, a patient can obtain a compound by them selves without theinvolvement of a health care practitioner. Administration of thecompound may or m ay not involve the patient actually internalizing thecompound. In the case where a patient internalizes the compound the bodyis transformed by the compound in some way.

PRESCRIBING: As used herein, “prescribing” means to order, authorize orrecommend the use of a drug or other therapy, remedy or treatment. Insome embodiments, a health care practitioner can orally advise,recommend or authorize the use of a compound, dosage regimen or othertreatment to a patient. In this case the health care practitioner may ormay not provide a prescription for the compound, dosage regimen ortreatment. Further, the health care practitioner may or may not providethe recommended compound or treatment. For example, the health carepractitioner can advise the patient where to obtain the compound withoutproviding the compound. In some embodiments, a health care practitionercan provide a prescription for the compound, dosage regimen or treatmentto the patient. For example, a health care practitioner can give awritten or oral prescription to a patient, A prescription can be writtenon paper or on electronic media such as a computer file, for example, ona hand held computer device. For example, a health care practitioner cantransform a piece of paper or electronic media with a prescription for acompound, dosage regimen or treatment. In addition, a prescription canbe called in (oral) or faxed in (written) to a pharmacy or a dispensary.In some embodiments, a sample of the compound or treatment can be givento the patient. As used herein, giving a sample of a compoundconstitutes an implicit prescription for the compound. Different healthcare systems around the world use different methods for prescribingand/or administering compounds or treatments and these methods areencompassed by the disclosure.

A prescription can include, for example, a patient's name and/oridentifying information such as date of birth. In addition, for example,a prescription can include, the medication name, medication strength,dose, frequency of administration, route of administration, number oramount to be dispensed, number of refills, physician name, physiciansignature. Further, for example, a prescription can include a DEA numberor state number.

A healthcare practitioner can include, for example, a physician, nurse,nurse practitioner or other related health care professional who canprescribe or administer compounds (drugs) for weight management. Inaddition, a healthcare practitioner can include anyone who canrecommend, prescribe, administer or prevent a patient from receiving acompound or drug, including, for example, an insurance provider.

PREVENT, PREVENTING, OR PREVENTION: As used herein, the term “prevent,”“preventing” or “prevention” such as prevention of obesity meansprevention of the occurrence or onset of one or more symptoms associatedwith a particular disorder and does not necessarily mean the completeprevention of a disorder. For example, the term “prevent,” “preventing”and “prevention” refers to the administration of therapy on aprophylactic or preventative basis to a patient who may ultimatelymanifest at least one symptom of a disease or condition but who has notyet done so. Such patients can be identified on the basis of riskfactors that are known to correlate with the subsequent occurrence ofthe disease. Alternatively, prevention therapy can be administeredwithout prior identification of a risk factor, as a prophylacticmeasure. Delaying the onset of toe at least one symptom can also beconsidered prevention or prophylaxis.

TREAT, TREATING, OR TREATMENT: As used herein the term “treat,”“treating” or “treatment” refers to the administration of therapy to apatient who already manifests at least one symptom of a disease orcondition or who has previously manifested at least one symptom of adisease or condition. For example, “treating” can include alleviating,abating or ameliorating a disease or condition symptoms, preventingadditional symptoms, ameliorating the underlying metabolic causes ofsymptoms, inhibiting the disease or condition, e.g., arresting thedevelopment of the disease or condition, relieving the disease orcondition, causing regression of the disease or condition, relieving acondition caused by the disease or condition, or stopping the symptomsof the disease or condition. For example, the term “treating” inreference to a disorder means a reduction in severity of one or moresymptoms associated with a particular disorder. Therefore, treating adisorder does not necessarily mean a reduction in severity of allsymptoms associated with a disorder and does not necessarily mean acomplete reduction in the severity of one or more symptoms associatedwith a disorder.

TOLERATE: As used herein, a patient is said to “tolerate” a dose of acompound if administration of that dose to that patient does not resultin an unacceptable adverse event or an unacceptable combination ofadverse events. One of skill in the art will appreciate that toleranceis a subjective measure and that what may be tolerable to one patientmay not be tolerable to a different patient. For example, one patientmay not be able to tolerate headache, whereas a second patient may findheadache tolerable but is not able to tolerate vomiting, whereas for athird patient, either headache alone or vomiting alone is tolerable, butthe patient is not able to tolerate the combination of headache andvomiting, even if the severity of each is less than when experiencedalone.

ADVERSE EVENT: As used herein, an “adverse event” is an untoward medicaloccurrence that is associated with treatment with Compound 1 or apharmaceutically acceptable salt, solvate or hydrate thereof. In oneembodiment, an adverse event is selected from headache, nausea,vomiting, and jaw pain. In one embodiment, an adverse event is selectedfrom headache, nausea, vomiting, jaw pain, flushing, abnormal pulserate, abnormal QT interval, sitting systolic blood pressure >160 mmHg,sitting diastolic blood pressure >100 mmHg, systolic blood pressure <90mmHg, or a combination of one more of the foregoing. In one embodiment,an adverse event is selected from abdominal pain, nosebleed, muscleaches, feeling of warmth, palpitations, dizziness, itching, diarrhea,chest pressure, joint aches, prickling or tingling skin sensation, andlowering of blood pressure. In one embodiment, an adverse event isselected from chest pain, chest discomfort, and erythema.

OPTIMIZED DOSE: As used herein, an “optimized dose” refers a therapeuticdose optimized to the needs of a specific patient and is the highestdose of Compound 1, or the dose of a pharmaceutically acceptable salt,solvate, or hydrate thereof that is equivalent to the highest dose ofCompound 1, that elicits the biological or medicinal response in thepatient that is being sought and that can be tolerated by the patient,as determined by the patient, optionally in consultation with thepatient's healthcare practitioner. The amount of Compound 1 in anoptimized dose may vary between patients. Further, the amount ofCompound 1 may vary from time to time for a given patient.

UP-TITRATION: As used herein, “up-titration” of a compound refers toincreasing the amount of a compound until the patient does not toleratethe increased amount. Up-titration can be achieved in one or more doseincrements, which may be the same or different. In some embodiments, themethod comprises prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, solvate or hydrate thereof in anamount equivalent to 0.01 mg of Compound 1 2 times daily for about oneweek, followed by up-titration as disclosed herein until an optimizeddose is administered. Administration of the optimized dose twice dailymay then continue as long as necessary, in some embodiments, the methodcomprises prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, solvate or hydrate thereof in anamount equivalent to 0.01 mg of Compound 1 once daily for about oneweek, followed by up-titration to an amount equivalent to 0.01 mg ofCompound 1 twice daily for about one week, followed by up-titration asdisclosed herein until an optimized dose is administered. Administrationof the optimized dose twice daily may then continue as long asnecessary.

It is understood that when the phrase “pharmaceutically acceptablesalts, solvates and hydrates” or the phrase “pharmaceutically acceptablesalt, solvate or hydrate” is used when referring to Compound 1, itembraces pharmaceutically acceptable solvates and/or hydrates ofCompound 1, pharmaceutically acceptable salts of Compound 1, as well aspharmaceutically acceptable solvates and/or hydrates of pharmaceuticallyacceptable salts of Compound 1. It is also understood that when thephrase “pharmaceutically acceptable solvates and hydrates” or the phrase“pharmaceutically acceptable solvate or hydrate” is used when referringto Compound 1 that are salts, it embraces pharmaceutically acceptablesolvates and/or hydrates of such salts.

It will be apparent to those skilled in the art that the dosage formsdescribed herein may comprise, as the active component, either Compound1 or a pharmaceutically acceptable salt or as a solvate or hydratethereof. Moreover, various hydrates and solvates of Compound 1 and theirsalts will find use as intermediates in the manufacture ofpharmaceutical compositions. Typical procedures for making andidentifying suitable hydrates and solvates, outside those mentionedherein, are well known to those in the art; see for example, pages202-209 of K. J. Guillory, “Generation of Polymorphs, Hydrates,Solvates, and Amorphous Solids,” in: Polymorphism in PharmaceuticalSolids, ed. Harry G. Britain, Vol. 95, Marcel Dekker, Inc., New York,1999. Accordingly, one aspect of the present disclosure pertains tomethods of prescribing and/or administering hydrates and solvates ofCompound 1 and/or its pharmaceutical acceptable salts, that can beisolated and characterized by methods known in the art, such as,thermogravimetric analysis (TGA), TGA-mass spectroscopy, TGA-Infraredspectroscopy, powder X-ray diffraction (XRPD), Karl Fisher titration,high resolution X-ray diffraction, and the like. There are severalcommercial entities that provide quick and efficient services foridentifying solvates and hydrates on a routine basis. Example companiesoffering these services include Wilmington PharmaTech (Wilmington,Del.), Avantium Technologies (Amsterdam) and Aptuit (Greenwich, Conn.).

The present disclosure includes all isotopes of atoms occurring in thepresent compounds, salts, solvates, and hydrates. Isotopes include thoseatoms having the same atomic number but different mass numbers. Oneaspect of the present invention includes every combination of one ormore atoms in the present compounds, salts, solvates, and hydrates thatis replaced with an atom having the same atomic number but a differentmass number. One such example is the replacement of an atom that is themost naturally abundant isotope, such as ¹H or ¹²C, found in one thepresent compounds, salts, solvates, and hydrates, with a different atomthat is not the most naturally abundant isotope, such as ²H or ³H(replacing ¹H), or ¹¹C, ¹³C, or ¹⁴C (replacing ¹²C). A salt wherein sucha replacement has taken place is commonly referred to as beingisotopically-labeled. Isotopic-labeling of the present compounds, salts,solvates, and hydrates can be accomplished using any one of a variety ofdifferent synthetic methods know to those of ordinary skill in the artand they are readily credited with understanding the synthetic methodsand available reagents needed to conduct such isotopic-labeling. By wayof general example, and without limitation, isotopes of hydrogen include²H (deuterium) and ³H (tritium). Isotopes of carbon include ¹¹C, ¹³C,and ¹⁴C. Isotopes of nitrogen include ¹³N and ¹⁵N. Isotopes of oxygeninclude ¹⁵O, ¹⁷O, and ¹⁸C. An isotope of fluorine includes ¹⁸F. Anisotope of sulfur includes ³⁵S. An isotope of chlorine includes ³⁶Cl.Isotopes of bromine include ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, and ⁸²Br. Isotopes ofiodine include ¹²³I, ¹²⁴I, ¹²⁵I, and ¹³⁵I. Another aspect of the presentinvention includes compositions, such as, those prepared duringsynthesis, preformulation, and the like, and pharmaceuticalcompositions, such as, those prepared with the intent of using in amammal for the treatment of one or more of the disorders describedherein, comprising one or more of the present compounds, salts,solvates, and hydrates, wherein the naturally occurring distribution ofthe isotopes in the composition is perturbed. Another aspect of thepresent invention includes compositions and pharmaceutical compositionscomprising the compounds, salts, solvates, and hydrates, as describedherein wherein the salt is enriched at one or more positions with anisotope other than the most naturally abundant isotope. Methods arereadily available to measure such isotope perturbations or enrichments,such as, mass spectrometry, and for isotopes that are radio-isotopesadditional methods are available, such as, radio-detectors used inconnection with HPLC or GC.

As used herein, the term “greater than” is used interchangeably with thesymbol > and the term less than is used interchangeably with the symbol<. Likewise the term less than or equal to is interchangeably with thesymbol ≤.

When an integer is used in a method disclosed herein, the term “about”can be inserted before the integer.

Throughout this specification, unless the context requires otherwise,the word “comprise”, or variations such as “comprises” or “comprising”will be understood to imply the inclusion of a stated step or element orinteger or group of steps or elements or integers but not the exclusionof any other step or element or integer or group of elements orintegers.

Throughout this specification, unless specifically stated otherwise orthe context requires otherwise, reference to a single step, compositionof matter, group of steps or group of compositions of matter shall betaken to encompass one and a plurality (i.e. one or more) of thosesteps, compositions of matter, groups of steps or group of compositionsof matter.

Each embodiment described herein is to be applied mutatis mutandis toeach and every other embodiment unless specifically stated otherwise.

Those skilled in the art will appreciate that the invention(s) describedherein is susceptible to variations and modifications other than thosespecifically described. It is to be understood that the invention(s)includes all such variations and modifications. The invention(s) alsoincludes all of the steps, features, compositions and compounds referredto or indicated in this specification, individually or collectively, andany and all combinations or any two or more of said steps or featuresunless specifically stated otherwise.

The present invention(s) is not to be limited in scope by the specificembodiments described herein, which are intended for the purpose ofexemplification only. Functionally-equivalent products, compositions andmethods are clearly within the scope of the invention(s), as describedherein.

It is appreciated that certain features of the invention(s), which are,for clarity, described in the context of separate embodiments, can alsobe provided in combination in a single embodiment. Conversely, variousfeatures of the invention(s), which are, for brevity, described in thecontext of a single embodiment, can also be provided separately or inany suitable subcombination. For example, a method that recitesprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, solvate or hydrate thereof can be separated into twomethods; one reciting prescribing Compound 1 or a pharmaceuticallyacceptable salt, solvate or hydrate thereof and the other recitingadministering Compound 1 or a pharmaceutically acceptable salt, solvateor hydrate thereof. In addition, for example, a method that recitesprescribing Compound 1 or a pharmaceutically acceptable salt, solvate orhydrate thereof and a separate method of the invention recitingadministering Compound 1 or a pharmaceutically acceptable salt, solvateor hydrate thereof can be combined into a single method recitingprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, solvate or hydrate thereof.

Provided is a method of treating pulmonary arterial hypertensioncomprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a pharmaceutically acceptable salt, hydrate, or        solvate thereof,    -   wherein the Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, is administered via a titration        scheme that comprises the up-titration of Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        over a period of no more than about nine weeks until an        optimized dose is administered.

Also provided is a method of determining an optimized dose for a patientin need of treatment of pulmonary arterial hypertension, comprising

-   -   prescribing and/or administering to the patient Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        and    -   increasing the dose of Compound 1, or a pharmaceutically        acceptable salt, hydrate, or solvate thereof, over a period of        no more than about nine weeks, until the optimized dose for the        patient is administered.

Also provided is a method of determining an optimized dose for a patientin need of treatment with Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, comprising:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        to the patient at an initial dose equivalent to 0.01 mg of        Compound 1 once daily for about one week; and    -   determining whether the patient tolerates the initial dose;        wherein if the patient tolerates the initial dose, the dose is        increased to a dose equivalent to 0.01 mg of Compound 1 twice        daily;        wherein if the patient does not tolerate the initial dose, the        optimized dose for the patient is less than a dose equivalent to        0.01 mg of Compound 1 once daily.

In some embodiments, the method of determining the optimized dose forthe patient in need thereof further comprises:

-   -   determining whether the patient tolerates the dose equivalent to        0.01 mg of Compound 1 twice daily;    -   wherein if the patient tolerates the dose equivalent to 0.01 mg        of Compound 1 twice daily, the dose is increased by an amount        equal to a first incremental value;    -   wherein if the patient does not tolerate the dose equivalent to        0.01 mg of Compound 1 twice daily, the optimized dose for the        patient is less than a dose equivalent to 0.01 mg of Compound 1        twice daily.

In some embodiments, the method of determining the optimized dose forthe patient in need thereof further comprises:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        to the patient at the increased dose for about one week; and    -   determining whether the patient tolerates the increased dose;    -   wherein if the patient tolerates the increased dose, the dose is        further increased by an amount equal to a second incremental        value, wherein the second incremental value is the same or        different from the first incremental value;    -   wherein if the patient does not tolerate the increased dose, the        optimized dose for the patient is equal to the difference        between the increased dose and the first incremental value.

Also provided is a method of determining an optimized dose for a patientin need thereof comprises:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        at an initial dose equivalent to 0.01 mg of Compound 1 twice        daily for about one week; and    -   determining whether the patient tolerates the initial dose;    -   wherein if the patient tolerates the initial dose, the dose is        increased by an amount equal to a first incremental value; and    -   wherein if the patient does not tolerate the initial dose, the        optimized dose for the patient is less than the equivalent of        0.01 mg of Compound 1 twice daily.

In some embodiments, the method of determining an optimized dose for thepatient further comprises:

-   -   prescribing and/or administering Compound 1, or a        pharmaceutically acceptable salt, hydrate, or solvate thereof,        at the increased dose for about one week; and    -   determining whether the patient tolerates the increased dose;    -   wherein if the patient tolerates the increased dose, the dose is        further increased by an amount equal to a second incremental        value, wherein the second incremental value is the same or        different from the first incremental value;    -   wherein if the patient does not tolerate the increased dose, the        optimized dose for the patient is equal to the difference        between the increased dose and the first incremental value.

Also provided is a method of determining an optimized dose for a patientin need thereof comprising a cycle of:

-   -   prescribing and/or administering the increased dose for a period        of about one week;    -   further increasing the dose by an amount equal to an incremental        value; and    -   determining whether the patient tolerates the further increased        dose;    -   wherein the cycle is repeated so long as the patient tolerates        the further increased dose, wherein the incremental value at        each cycle repetition is the same or different; and    -   wherein if the patient does not tolerate the further increased        dose, the optimized dose for the patient is equal to the        difference between the further increased dose and the        incremental value for the last cycle repetition.

In some embodiments the method further comprises prescribing and/oradministering the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, to the patient.

In some embodiments the up-titration is performed over a period of about9 weeks.

In some embodiments the amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, administered to thepatient is increased at intervals of about equal time periods until theoptimized dose is administered. In some embodiments, the amount isincreased at about weekly intervals.

In some embodiments, the titration scheme comprises prescribing and/oradministering Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, at an initial dose equivalent to 0.01 mg ofCompound 1 twice daily for about one week and, provided that the patienttolerates the initial dose, increasing the dose.

In some embodiments, the titration scheme further comprises prescribingand/or administering Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, at the increased dose for about one weekand, provided that the patient tolerates the increased dose, furtherincreasing the dose.

In some embodiments, the titration scheme comprises a cycle ofprescribing and/or administering the increased dose for a period ofabout one week and then further increasing the dose, wherein the cycleis repeated so long as the patient tolerates the further increased dose,until an optimized dose is administered.

In some embodiments where the titration scheme comprises a cycle ofprescribing and/or administering the increased dose as disclosed herein,the cycle is repeated once. In some embodiments, the cycle is repeatedtwice. In some embodiments, the cycle is repeated three times. In someembodiments, the cycle is repeated four times. In some embodiments, thecycle is five times. In some embodiments, the cycle is repeated sixtimes. In some embodiments, the cycle is repeated seven times. In someembodiments, the cycle is repeated eight times. In some embodiments, thecycle is repeated nine times. In some embodiments, the cycle is notrepeated.

In some embodiments of the method of treating pulmonary arterialhypertension comprising administration via a titration scheme, thetitration scheme comprises a cycle of

-   1) prescribing and/or administering for a period of about one week a    dose that is higher by an incremental value than the dose for a    previous period, and-   2) determining whether the patient tolerates the higher dose for    such period of about one week;    -   wherein the cycle of steps 1) and 2) is repeated so long as the        patient tolerates the higher dose, wherein the incremental value        at every repetition of the cycle is the same or different from a        previous incremental value;    -   wherein if the patient does not tolerate the higher dose, the        optimized dose for the patient is equal to the difference        between the higher dose and the incremental value for the last        cycle repetition.

In some embodiments of the method of determining the optimized dose forthe patient in need thereof, the method comprises prescribing and/oradministering Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, over more than one period each of about oneweek, wherein the method comprises a cycle of

-   -   1) prescribing and/or administering for a period of about one        week a dose that is higher by an incremental value than the dose        for a previous period, and    -   2) determining whether the patient tolerates the higher dose for        such period of about one week;    -   wherein the cycle of steps 1) and 2) is repeated so long as the        patient tolerates the higher dose, wherein the incremental value        at every repetition of the cycle is the same or different from a        previous incremental value;    -   wherein if the patient does not tolerate the higher dose, the        optimized dose for the patient is equal to the difference        between the higher dose and the incremental value for the last        cycle repetition.

In some embodiments of the cycle of

-   -   1) prescribing and/or administering for a period of about one        week a dose that is higher by an incremental value than the dose        for a previous period, and    -   2) determining whether the patient tolerates the higher dose for        such period of about one week,    -   the higher dose administered is equal to an amount administered        twice daily that is higher than the amount administered twice        daily for a previous period is, and determining whether the        patient tolerates the higher dose comprises:    -   a) determining whether the patient tolerates the higher amount        administered twice daily;    -   b) if the patient does not tolerate the higher amount        administered twice daily, administering the higher amount once        daily to the patient;    -   c) if the patient tolerates the higher amount administered once        daily, re-administering the higher amount twice daily to the        patient; and    -   d) determining if the patient tolerates the higher amount        re-administered twice daily.

In some embodiments, determining whether the patient tolerates thehigher dose comprises:

-   -   a) determining whether the patient tolerates the higher amount        administered twice daily;    -   b) if the patient does not tolerate the higher amount        administered twice daily, administering the higher amount once        daily to the patient;    -   c) if the patient tolerates the higher amount administered once        daily, re-administering the higher amount twice daily to the        patient; and    -   d) determining if the patient tolerates the higher amount        re-administered twice daily.

In some embodiments, the patient does not tolerate the initial dose andthe optimized dose of Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, is less than the equivalent of 0.01 mg ofCompound 1 once daily. In some embodiments, the optimized dose ofCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, is the equivalent of 0.01 mg of Compound 1 administered at afrequency that is less than twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.01 mg of Compound 1 once daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.01 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.02 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.03 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.04 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.06 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.08 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.1 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.2 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.3 mg of Compound 1 twice daily.

In some embodiments, the optimized dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isequivalent to 0.6 mg of Compound 1 twice daily.

In some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, is administered orally.

In some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, is formulated as a capsule or tabletsuitable for oral administration. In some embodiments, the Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof, isformulated as a capsule.

In some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, is Compound 1, or a hydrate orsolvate thereof.

In some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, is Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.01 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.02 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.03 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.04 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.06 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.08 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.1 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.2 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.3 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.6 mg of Compound 1.

In some embodiments, provided here is a pharmaceutical compositioncomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.01 mg to 0.6 mg ofCompound 1, such as 0.01 mg to 0.3 mg of Compound 1, such as 0.01 mg to0.2 mg of Compound 1, such as 0.01 mg to 0.1 mg of Compound 1, such as0.02 mg to 0.08 mg of Compound 1, such as 0.03 mg to 0.06 mg of Compound1, such as such as 0.04 mg of Compound 1.

In some embodiments of the pharmaceutical composition, the compositionis in the form of a capsule or tablet. In some embodiments of thepharmaceutical composition, the composition is in the form of a capsule.In some embodiments of the pharmaceutical composition, the compositionis in the form of a tablet.

Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology.Vasoconstriction, remodeling of the pulmonary vessel wall, andthrombosis contribute to increased pulmonary vascular resistance in PAH(Humbert et al. J. Am. Coll. Cardiol, 2004, 43:13 S-24S.)

The compounds disclosed herein are useful in the treatment of pulmonaryarterial hypertension (PAH) and symptoms thereof. PAH shall beunderstood to encompass the following forms of pulmonary arterialhypertension described in the 2003 World Health Organization (WHO)clinical classification of pulmonary arterial hypertension: idiopathicPAH (IPAH); familial PAH (FPAH); PAH associated with other conditions(APAH), such as PAH associated with collagen vascular disease, PAHassociated with congenital systemic-to-pulmonary shunts, PAH associatedwith portal hypertension, PAH associated with HIV infection, PAHassociated with drugs or toxins, or PAH associated with Other; and PAHassociated with significant venous or capillary involvement.

Idiopathic PAH refers to PAH of undetermined cause.

Familial PAH refers to PAH for which hereditary transmission issuspected or documented.

PAH associated with collagen vascular disease shall be understood toencompass PAH associated with scleroderma, PAH associated with CREST(calcinosis cutis, Raynaud's phenomenon, esophageal dysfunction,sclerodactyl), and telangiectasias) syndrome, PAH associated withsystemic lupus erythematosus (SLE), PAH associated with rheumatoidarthritis, PAH associated with Takayasu's arteritis, PAH associated withpolymyositis, and PAH associated with dermatomyositis.

PAH associated with congenital systemic-to-pulmonary shunts shad beunderstood to encompass PAH associated with atrial septic defect (ASD),PAH associated with ventricular septic defect (VSD) and PAH associatedwith patent ductus arteriosus.

PAH associated with drugs or toxins shall be understood to encompass PAHassociated with ingestion of aminorex, PAH associated with ingestion ofa fenfluramine compound (e.g., PAH associated with ingestion offenfluramine or PAH associated with ingestion of dexfenfluramine), PAHassociated with ingestion of certain toxic oils (e.g., PAH associatedwith ingestion of rapeseed oil), PAH associated with ingestion ofpyrrolizidine alkaloids (e.g., PAH associated with ingestion of bushtea) and PAH associated with ingestion of monocrotaline.

PAH associated with Other shall be understood to encompass PAHassociated with a thyroid disorder, PAH associated with glycogen storagedisease, PAH associated with Gaucher disease, PAH associated withhereditary hemorrhagic telangiectasia, PAH associated with ahemoglobinopathy, PAH associated with a myeloproliferative disorder, andPAH associated with splenectomy.

PAH associated with significant venous or capillary involvement shall beunderstood to encompass PAH associated with pulmonary veno-occlusivedisease (PVOD) and PAH associated with pulmonary capillaryhemangiomatosis (PCH). (See, e.g., Simonneau et al. J. Am. Coll.Cardiol, 2004, 43:5 S-12S; McGoon et al. Chest, 2004, 126:14 S-34S;Rabinovitch, Annu, Rev. Pathol. Mech. Dis., 2007, 2:369-399; McLaughlinet al. Circulation, 2006, 114:1417-1431; Strauss et al. Clin, Chest.Med., 2007, 28:127-142; Taichman et al. Clin. Chest. Med., 2007,28:1-22.)

Evidence for the association of PAH with scleroderma and the beneficialeffect of an agonist of the PGI2 receptor on PAH is given by Badesch etah (Badesch et al. Ann. Intern. Med., 2000, 132:425-434). Evidence forthe association of PAH with the collagen vascular diseases mixedconnective tissue disease (MCTD), systemic lupus erythematosus (SLE),Sjogren's syndrome and CREST syndrome and the beneficial effect of anagonist of the PGI2 receptor on PAH is given by Humbert et al. (Eur.Respir. J., 1999, 13:1351-1356). Evidence for the association of PAHwith CREST syndrome and the beneficial effect of an agonist of the PGI2receptor on PAH is given by Miwa et al. (Int. Heart J., 2007,48:417422). Evidence for the association of PAH with SEE and thebeneficial effect of an agonist of the PGI2 receptor on PAH is given byRobbins et al. (Chest, 2000, 117:14-1.8). Evidence for the associationof PAH with HIV infection and the beneficial of an agonist of the PGI2receptor on PAH is given by Aguilar et al. (Am. J. Respir, Crit. CareMed., 2000, 162:1846-1850). Evidence for the association of PAH withcongenital heart defects (including ASD, VSD and patent ductusarteriosus) and the beneficial effect of an agonist of the PGI2 receptoron PAH is given by Rosenzweig et al. (Circulation, 1999, 99:1858-1865).Evidence for the association of PAH with fenfluramine and withdexfenfluramine, anorexigens, is given by Archer et al. (Am. J. Respir.Crit. Care Med., 1998, 158:1061-1067). Evidence for the association ofPAH with hereditary hemorrhagic telangiectasia is given by McGoon et al.(Chest, 2004, 126:14-34). Evidence for the association of PAH withsplenectomy is given by Hoeper et al. (Ann. Intern. Med., 1999,130:506-509). Evidence for the association of PAH with portalhypertension and the beneficial effect of an agonist of the PGI2receptor on PAH is given by Hoeper et al. (Eur. Respir. J., 2005,25:502-508).

Symptoms of PAH include dyspnea, angina, syncope and edema (McLaughlinet al. Circulation, 2006.114:1417-1431). The compounds disclosed hereinare useful in the treatment of symptoms of PAH.

In some embodiments, pulmonary arterial hypertension (PAH) is selectedfrom: idiopathic PAH; familial PAH; PAH associated with a collagenvascular disease selected from: scleroderma, CREST syndrome, systemiclupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH) in a patient.

Also provided are methods for the treatment of PAH in a patient in needthereof, comprising prescribing and/or administering to the patientCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein. Also provided are methods for the treatment of PAHin a patient in need thereof, comprising administering to the patientCompound 1 via a titration scheme as disclosed herein.

Also provided are methods for the treatment of idiopathic PAH in apatient in need thereof, comprising prescribing and/or administering tothe patient Compound 1 or a pharmaceutically acceptable salt, hydrate orsolvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided are methods for thetreatment of idiopathic PAH in a patient in need thereof, comprisingadministering to the patient Compound 1 via a titration scheme asdisclosed herein.

Also provided are methods for the treatment of familial PAH in a patientin need thereof, comprising prescribing and/or administering to thepatient Compound 1 or a pharmaceutically acceptable salt, hydrate orsolvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided are methods for thetreatment of familial PAH in a patient in need thereof, comprisingadministering to the patient Compound 1 via a titration scheme asdisclosed herein.

Also provided are methods for the treatment of PAH associated with acollagen vascular disease in a patient in need thereof, comprisingprescribing and/or administering to the patient Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided are methods for the treatment of PAH associatedwith a collagen vascular disease in a patient in need thereof,comprising administering to the patient Compound 1 via a titrationscheme as disclosed herein.

Also provided are methods for the treatment of PAH associated with acollagen vascular disease selected from: scleroderma. CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis in a patient in needthereof, comprising prescribing and/or administering to the patientCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein. Also provided are methods for the treatment of PAHassociated with a collagen vascular disease selected from: scleroderma,CREST syndrome, systemic lupus erythematosus (SEE), rheumatoidarthritis, Takayasu's arteritis, polymyositis, and dermatomyositis in apatient in need thereof, comprising administering to the patientCompound 1 via a titration scheme as disclosed herein.

Also provided are methods for the treatment of PAH associated with acongenital heart disease in a patient in need thereof, comprisingprescribing and/or administering to the patient Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided are methods for the treatment of PAH associatedwith a congenital heart disease in a patient in need thereof, comprisingadministering to the patient Compound 1 via a titration scheme asdisclosed herein.

Also provided are methods for the treatment of PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient in need thereof, comprising prescribing and/or administering tothe patient Compound 1 or a pharmaceutically acceptable salt, hydrate orsolvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided are methods for thetreatment of PAH associated with a congenital heart disease selectedfrom: atrial septic defect (ASD), ventricular septic defect (VSD) andpatent ductus arteriosus in a patient in need thereof, comprisingadministering to the patient Compound 1 via a titration scheme asdisclosed herein.

Also provided are methods for the treatment of PAH associated withportal hypertension in a patient in need thereof, comprising prescribingand/or administering to the patient Compound 1 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided are methods for the treatment of PAH associated with portalhypertension in a patient in need thereof, comprising administering tothe patient Compound 1 via a titration scheme as disclosed herein.

Also provided are methods for the treatment of PAH associated with HIVinfection in a patient in need thereof, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein. Also provided aremethods for the treatment of PAH associated with HIV infection in apatient in need thereof, comprising administering to the patientCompound 1 via a titration scheme as disclosed herein.

Also provided are methods for the treatment of PAH associated withingestion of a drug or toxin in a patient in need thereof, comprisingprescribing and/or administering to the patient Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided are methods for the treatment of PAH associatedwith ingestion of a drug or toxin in a patient in need thereof,comprising administering to the patient Compound 1 via a titrationscheme as disclosed herein.

Also provided are methods for the treatment of PAH associated withhereditary hemorrhagic telangiectasia in a patient in need thereof,comprising prescribing and/or administering to the patient Compound 1 ora pharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided are methods for the treatment of PAH associatedwith hereditary hemorrhagic telangiectasia in a patient in need thereof,comprising administering to the patient Compound 1 via a titrationscheme as disclosed herein.

Also provided are methods for the treatment of PAH associated withsplenectomy in a patient in need thereof, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein. Also provided aremethods for the treatment of PAH associated with splenectomy in apatient in need thereof, comprising administering to the patientCompound 1 via a titration scheme as disclosed herein.

Also provided are methods for the treatment of PAH associated withsignificant venous or capillary involvement in a patient in needthereof, comprising prescribing and/or administering to the patientCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein. Also provided are methods for the treatment of PAHassociated with significant venous or capillary involvement in a patientin need thereof, comprising administering to the patient Compound 1 viaa titration scheme as disclosed herein.

Also provided are methods for the treatment of PAH associated withpulmonary veno-occlusive disease (PVOD) in a patient in need thereof,comprising prescribing and/or administering to the patient Compound 1 ora pharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided are to methods for tire treatment of PAHassociated with pulmonary veno-occlusive disease (PVOD) in a patient inneed thereof, comprising administering to the patient Compound 1 via atitration scheme as disclosed herein.

Also provided are methods for the treatment of PAH associated withpulmonary capillary hemangiomatosis (PCH) in a patient in need thereof,comprising prescribing and/or administering to the patient Compound 1 ora pharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided are methods for the treatment of PAH associatedwith pulmonary capillary hemangiomatosis (PCH) in a patient in needthereof, comprising administering to the patient Compound 1 via atitration scheme as disclosed herein.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.01 mg of Compound 1 once daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.01 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.02 mg of Compound 1 twice daily, insome embodiments of the methods for the treatment of PAH in a patient inneed thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.03 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.04 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.06 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.08 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.1 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.2 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.3 mg of Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH in a patientin need thereof disclosed herein, comprising prescribing and/oradministering to the patient Compound 1 or a pharmaceutically acceptablesalt, hydrate or solvate thereof, or a pharmaceutical compositionthereof, via a titration scheme as disclosed herein, the optimized doseof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, is equivalent to 0.6 mg of Compound 1 twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.01 mg of Compound 1, once daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.01 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.02 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.03 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.04 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.06 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.08 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.1 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.2 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.3 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.6 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment ofPAH, the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.01 mg to 0.6 mg of Compound 1, twice daily, such as 0.01mg to 0.3 mg of Compound 1, twice daily, such as 0.01 mg to 0.2 mg ofCompound 1, twice daily, such as 0.01 mg to 0.1 mg of Compound 1, twicedaily, such as 0.02 mg to 0.08 mg of Compound 1, twice daily, such as0.03 mg to 00.6 mg of Compound 1, twice daily, such as such as 0.04 mgof Compound 1 twice daily.

In some embodiments of the methods for the treatment of PAH, theCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, is formulated as a capsule or tablet suitable for oraladministration. In some embodiments, the Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isformulated as a capsule. In some embodiments, the Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isformulated as a tablet.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.01 mg of Compound 1, once daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.01 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.02 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated washHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.03 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), tire method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.04 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVQD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.06 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.08 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.1 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.2 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.3 mg of Compound 1, twice daily.

In some embodiments provided herein is a method for the treatment of PAHselected from: idiopathic PAH; familial PAH; PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis; PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus in apatient; PAH associated with portal hypertension; PAH associated withHIV infection; PAH associated with ingestion of a drug or toxin; PAHassociated with hereditary hemorrhagic telangiectasia; PAH associatedwith splenectomy; PAH associated with significant venous or capillaryinvolvement; PAH associated with pulmonary veno-occlusive disease(PVOD); and PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering to thepatient a pharmaceutical composition comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.6 mg of Compound 1, twice daily.

In some embodiments of the methods for the treatment of PAH selectedfrom: idiopathic PAH; familial PAH; PAH associated with a collagenvascular disease selected from: scleroderma, CREST syndrome, systemiclupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), the Compound1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof,is formulated as a capsule or tablet suitable for oral administration.In some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, is formulated as a capsule. In someembodiments, the Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, is formulated as a tablet.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.01 mg ofCompound 1, once daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.01 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.02 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.03 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.04 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.06 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.08 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.1 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.2 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.3 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.6 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.01 mg to0.6 mg of Compound 1, twice daily, such as 0.01 mg to 0.3 mg of Compound1, twice daily, such as 0.01 mg to 0.2 mg of Compound 1, twice daily,such as 0.01 mg to 0.1 mg of Compound 1, twice daily, such as 0.02 mg to0.08 mg of Compound 1, twice daily, such as 0.03 mg to 0.06 mg ofCompound 1, twice daily, such as such as 0.04 mg of Compound 1 twicedaily.

In some embodiments of the methods for the treatment of PAH, theCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, is formulated as a capsule or tablet suitable for oraladministration, in some embodiments, the Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isformulated as a capsule, in some embodiments, the Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, isformulated as a tablet.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.01 mg ofCompound 1, once daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.01 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.02 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.03 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.04 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceutical,composition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.06 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.08 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.5 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.2 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.3 mg ofCompound 1, twice daily.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), comprisingprescribing and/or administering to the patient a pharmaceuticalcomposition comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.6 mg ofCompound 1, twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH selected from:idiopathic PAH; familial PAH; PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis; PAH associated with a congenitalheart disease selected from: atrial septic defect (ASD), ventricularseptic defect (VSD) and patent ductus arteriosus in a patient; PAHassociated with portal hypertension; PAH associated with HIV infection;PAH associated with ingestion of a drug or toxin; PAH associated withhereditary hemorrhagic telangiectasia; PAH associated with splenectomy;PAH associated with significant venous or capillary involvement; PAHassociated with pulmonary veno-occlusive disease (PVOD); and PAHassociated with pulmonary capillary hemangiomatosis (PCH), the Compound1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof,is formulated as a capsule or tablet suitable for oral administration,in some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, is formulated as a capsule. In someembodiments, the Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, is formulated as a tablet.

In some embodiments of the pharmaceutical composition or of the methodfor the treatment of PAH selected from: idiopathic PAH; familial PAH;PAH associated with a collagen vascular disease selected from:scleroderma, CREST syndrome, systemic lupus erythematosus (SLE),rheumatoid arthritis, Takayasu's arteritis, polymyositis, anddermatomyositis; PAH associated with a congenital heart disease selectedfrom: atrial septic defect (ASD), ventricular septic defect (VSD) andpatent ductus arteriosus in a patient; PAH associated with portalhypertension; PAH associated with HIV infection; PAH associated withingestion of a drug or toxin; PAH associated with hereditary hemorrhagictelangiectasia; PAH associated with splenectomy; PAH associated withsignificant venous or capillary involvement; PAH associated withpulmonary veno-occlusive disease (PVQD); and PAH associated withpulmonary capillary hemangiomatosis (PCH), the dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, iseffective in in producing a difference of at least about 40 meters in6MWD relative to the 6MWD prior to administration of the dose.

In some embodiments of the pharmaceutical composition or of the methodfor the treatment of PAH selected from: idiopathic PAH; familial PAH;PAH associated with a collagen vascular disease selected from:scleroderma, CREST syndrome, systemic lupus erythematosus (SLE),rheumatoid arthritis, Takayasu's arteritis, polymyositis, anddermatomyositis; PAH associated with a congenital heart disease selectedfrom: atrial septic defect (ASD), ventricular septic defect (VSD) andpatent ductus arteriosus in a patient; PAH associated with portalhypertension; PAH associated with HIV infection; PAH associated withingestion of a drug or toxin; PAH associated with hereditary hemorrhagictelangiectasia; PAH associated with splenectomy; PAH associated withsignificant venous or capillary involvement; PAH associated withpulmonary veno-occlusive disease (PVOD); and PAH associated withpulmonary capillary hemangiomatosis (PCH), the dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, iseffective in producing a difference of at least about 45 meters in 6MWDrelative to the 6MWD prior to administration of the dose.

In some embodiments of the pharmaceutical composition or of the methodfor the treatment of PAH selected from: idiopathic PAH; familial PAH;PAH associated with a collagen vascular disease selected from:scleroderma, CREST syndrome, systemic lupus erythematosus (SLE),rheumatoid arthritis, Takayasu's arteritis, polymyositis, anddermatomyositis; PAH associated with a congenital heart disease selectedfrom: atrial septic defect (ASD), ventricular septic defect (VSD) andpatent ductus arteriosus in a patient; PAH associated with portalhypertension; PAH associated with HIV infection; PAH associated withingestion of a drug or toxin; PAH associated with hereditary hemorrhagictelangiectasia; PAH associated with splenectomy; PAH associated withsignificant venous or capillary involvement; PAH associated withpulmonary veno-occlusive disease (PVOD); and PAH associated withpulmonary capillary hemangiomatosis (PCH), the dose of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, iseffective in producing a difference of at least about 50 meters in 6MWDrelative to the 6MWD prior to administration of the dose.

As used herein “6MWD” refers to “six-minute walk distance”, that is, thedistance that the patient covers by walking for a six-minute period. Insome embodiments, the 6MWD is the distance that the patient covers bywalking for a six-minute period along an indoor surface. In someembodiments, the 6MWD is the distance that the patient covers by walkingfor a six-minute period along a flat indoor surface that is about 15 toabout 50 meters in length, turning around every time the patient reachesa preset turnaround point on the surface.

In some embodiments, the 6MWD is determined according to the AmericanThoracic Society guidelines for the Six-minute Walk Test (“6MWT”)disclosed in Am. J Respir. Crit. Care Med Vol. 166, p. 111-117, 2002;DOI: 10.1164/rccm.166/1/111, incorporated by reference herein in itsentirety; also available athttps://www.thoracic.org/statements/resources/pfet/sixminute.pdf.

In some embodiments of the 6MWD, equipment that may be used or presentin the vicinity may include O₂ saturation equipment and forehead probes;a countdown timer or stopwatch; a mechanical lap counter; two smallcones to mark the turnaround points; a chair that can be moved along thewalking course; worksheets; a source of oxygen; a telephone; and anautomated electronic defibrillator. The subject may prepare for the 6MWTby wearing comfortable clothing and appropriate shoes for walking; usingany walking aids during the test, such as a cane or a walker; continuingany medical regimen including taking Compound 1 before the commencementof the 6MWT; eating alight meal before early morning or early afternoon6MWTs; and avoiding vigorous exercise within 2 hours of beginning thetest. Prior to the test the subject may sit at rest in a chair locatednear the starting position, for at least 10 minutes. Information thatmay be recorded includes one or more of the following: startinglocation, length of hallway, direction the subject walks, time of test,and subject's general condition.

The 6MWT may be immediately stopped for reasons that include thefollowing: (1) chest pain, (2) intolerable dyspnea, (3) leg cramps, (4)staggering, (5) diaphoresis, and (6) pale or ashen appearance. Subjectswho require supplemental oxygen must breathe a stable oxygen dose for atleast 15 minutes prior to the measurement of O₂ saturation and until theend of the 6MWT. Absolute contraindications for the 6MWT include thefollowing: unstable angina during the previous month and myocardialinfarction during the previous month. Relative contraindications includea resting HR of more than 120, a sBP of more them 180 mmHg, and a dBP ofmore than 100 mmHg.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is the use of Compound Lora pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising administering Compound 1 via a titration scheme as disclosedherein.

Also provided is the use of a Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of idiopathic PAH, thetreatment comprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is the use of a Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of idiopathic PAH, thetreatment comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of familial PAH, thetreatment comprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of familial PAH, thetreatment comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated with acollagen vascular disease, the treatment comprising prescribing and/oradministering Compound 1 or a pharmaceutically acceptable salt, hydrateor solvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided is the use ofCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, as described herein, in the manufacture of a medicament for thetreatment of PAH associated with a collagen vascular disease, thetreatment comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis, the treatment comprisingprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated with acollagen vascular disease selected from: scleroderma, CREST syndrome,systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu'sarteritis, polymyositis, and dermatomyositis, the treatment comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated with acongenital heart disease, the treatment comprising prescribing and/oradministering Compound 1 or a pharmaceutically acceptable salt, hydrateor solvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided is the use ofCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, as described herein, in the manufacture of a medicament for thetreatment of PAH associated with a congenital heart disease, thetreatment comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated with acongenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus, thetreatment comprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH associated witha congenital heart disease selected from: atrial septic defect (ASD),ventricular septic defect (VSD) and patent ductus arteriosus, thetreatment comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withportal hypertension, the treatment comprising prescribing and/oradministering Compound 1 or a pharmaceutically acceptable salt, hydrateor solvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided is the use ofCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, as described herein, in the manufacture of a medicament for thetreatment of PAH associated with portal hypertension, the treatmentcomprising administering Compound 1 via a titration scheme as disclosedherein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated with HIVinfection, the treatment comprising prescribing and/or administeringCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein. Also provided is the use of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, asdescribed herein, in the manufacture of a medicament for the treatmentof PAH associated with HIV infection, the treatment comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withingestion of a drug or toxin, the treatment comprising prescribingand/or administering Compound 1 or a pharmaceutically acceptable salt,hydrate or solvate thereof, or a pharmaceutical composition thereof, viaa titration scheme as disclosed herein. Also provided is the use ofCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, as described herein, in the manufacture of a medicament for thetreatment of PAH associated with ingestion of a drug or toxin, thetreatment comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withhereditary hemorrhagic telangiectasia, the treatment comprisingprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withhereditary hemorrhagic telangiectasia, the treatment comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withsplenectomy, the treatment comprising prescribing and/or administeringCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein. Also provided is the use of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, asdescribed herein, in the manufacture of a medicament for the treatmentof PAH associated with splenectomy, the treatment comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withsignificant venous or capillary involvement, the treatment comprisingprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withsignificant venous or capillary involvement, the treatment comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withpulmonary veno-occlusive disease (PVQD), the treatment comprisingprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withpulmonary veno-occlusive disease (PVOD), the treatment comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withpulmonary capillary hemangiomatosis (PCH), the treatment comprisingprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided is the use of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH associated withpulmonary capillary hemangiomatosis (PCH), the treatment comprisingadministering Compound 1 via a titration scheme as disclosed herein.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.01 mgof Compound 1 once daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.01 mgof Compound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt-hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.02 mgof Compound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.03 mgof Compound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.04 mgof Compound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt-hydrate, or solvate thereof, as described herein, in themanufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.06 mgof Compound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.08 mgof Compound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.1 mg ofCompound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.2 mg ofCompound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.3 rugof Compound 1 twice daily.

In some embodiments of the use of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, inthe manufacture of a medicament for the treatment of PAH, the treatmentcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein, the optimized dose of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, is equivalent to 0.6 mg ofCompound 1 twice daily.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH, the method comprising prescribing and/or administeringCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH, the method comprising administering Compound 1 via atitration scheme as disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of idiopathic PAH, the method comprising prescribing and/oradministering Compound 1 or a pharmaceutically acceptable salt, hydrateor solvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided is Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, asdescribed herein, for use in a method of treatment of idiopathic PAH,the method comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of familial PAH, the method comprising prescribing and/oradministering Compound 1 or a pharmaceutically acceptable salt, hydrateor solvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided is Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, asdescribed herein, for use in a method of treatment of familial PAH, themethod comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with a collagen vascular disease, the methodcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, for use in amethod of treatment of PAH associated with a collagen vascular disease,the method comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with a collagen vascular disease selectedfrom: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE),rheumatoid arthritis, Takayasu's arteritis, polymyositis, anddermatomyositis, the method comprising prescribing and/or administeringCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein. Also provided is Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, foruse in a method of treatment of PAH associated with a collagen vasculardisease selected from: scleroderma, CREST syndrome, systemic lupuserythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,polymyositis, and dermatomyositis, the method comprising administeringCompound 1 via a titration scheme as disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with a congenital heart disease, the methodcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, for use in amethod of treatment of PAH associated with a congenital heart disease,the method comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with a congenital heart disease selectedfrom: atrial septic defect (ASD), ventricular septic defect (VSD) andpatent ductus arteriosus, the method comprising prescribing and/oradministering Compound 1 or a pharmaceutically acceptable salt, hydrateor solvate thereof, or a pharmaceutical composition thereof, via atitration scheme as disclosed herein. Also provided is Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, asdescribed herein, for use in a method of treatment of PAH associatedwith a congenital heart disease selected from: atrial septic defect(ASD), ventricular septic defect (VSD) and patent ductus arteriosus, themethod comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with portal hypertension, the methodcomprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, for use in amethod of treatment of PAH associated with portal hypertension, themethod comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with HIV infection, the method comprisingprescribing and/or administering Compound 1 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided is Compound 1, or a pharmaceutically acceptable salt, hydrate,or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with HIV infection, the method comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with ingestion of a drug or toxin, themethod comprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, for use in amethod of treatment of PAH associated with ingestion of a drug or toxin,the method comprising administering Compound 1 via a titration scheme asdisclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with hereditary hemorrhagic telangiectasia,the method comprising prescribing and/or administering Compound 1 or apharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, for use in amethod of treatment of PAH associated with hereditary hemorrhagictelangiectasia, the method comprising administering Compound 1 via atitration scheme as disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with splenectomy, the method comprisingprescribing and/or administering Compound 3 or a pharmaceuticallyacceptable salt, hydrate or solvate thereof, or a pharmaceuticalcomposition thereof, via a titration scheme as disclosed herein. Alsoprovided is Compound 1, or a pharmaceutically acceptable salt, hydrate,or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with splenectomy, the method comprisingadministering Compound 1 via a titration scheme as disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with significant venous or capillaryinvolvement, the method comprising prescribing and/or administeringCompound 1 or a pharmaceutically acceptable salt, hydrate or solvatethereof, or a pharmaceutical composition thereof, via a titration schemeas disclosed herein. Also provided is Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, foruse in a method of treatment of PAH associated with significant venousor capillary involvement, the method comprising administering Compound 1via a titration scheme as disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with pulmonary veno-occlusive disease(PVOD), the method comprising prescribing and/or administering Compound1 or a pharmaceutically acceptable salt, hydrate or solvate thereof, ora pharmaceutical composition thereof, via a titration scheme asdisclosed herein. Also provided is Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, as described herein, foruse in a method of treatment of PAH associated with pulmonaryveno-occlusive disease (PVOD), the method comprising administeringCompound 1 via a titration scheme as disclosed herein.

Also provided is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, as described herein, for use in a method oftreatment of PAH associated with pulmonary capillary hemangiomatosis(PCH), the method comprising prescribing and/or administering Compound 1or a pharmaceutically acceptable salt, hydrate or solvate thereof, or apharmaceutical composition thereof, via a titration scheme as disclosedherein. Also provided is Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, as described herein, for use in amethod of treatment of PAH associated with pulmonary capillaryhemangiomatosis (PCH), the method comprising administering Compound 1via a titration scheme as disclosed herein.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a    -   pharmaceutically acceptable salt, hydrate, or solvate thereof,        at an initial dose as disclosed herein;    -   administering Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, via a titration scheme as disclosed        herein until an optimized dose is administered; and        prescribing or administering the optimized dose twice daily to        the patient for about 13 weeks.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a pharmaceutically acceptable salt, hydrate, or        solvate thereof, at an initial dose as disclosed herein;    -   administering Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, via a titration scheme as disclosed        herein until an optimized dose is administered; and    -   prescribing or administering the optimized dose twice daily to        the patient for about 13 weeks to produce a difference of at        least about 40 meters in 6MWD by the patient relative to the        6MWD prior to administration of the initial dose.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a    -   pharmaceutically acceptable salt, hydrate, or solvate thereof,        at an initial dose as disclosed herein;    -   administering Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, via a titration scheme as disclosed        herein until an optimized dose is administered; and    -   prescribing or administering the optimized dose twice daily to        the patient for about 13 weeks to produce a difference of at        least about 45 meters in 6MWD by the patient relative to the        6MWD prior to administration of the initial dose.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a    -   pharmaceutically acceptable salt, hydrate, or solvate thereof,        at an initial dose as disclosed herein;    -   administering Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, via a titration scheme as disclosed        herein until an optimized dose is administered; and    -   prescribing or administering the optimized dose twice daily to        the patient for about 13 weeks to produce a difference of at        least about 50 meters in 6MWD by the patient relative to the        6MWD prior to administration of the initial dose.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a    -   pharmaceutically acceptable salt, hydrate, or solvate thereof,        at an initial dose as disclosed herein;    -   administering Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, via a titration scheme as disclosed        herein until an optimized dose is administered; and    -   prescribing or administering the optimized dose twice daily to        the patient for a time sufficient to produce a difference of at        least about 40 meters in 6MWD by the patient relative to the        6MWD prior to administration of the initial dose.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a    -   pharmaceutically acceptable salt, hydrate, or solvate thereof,        at an initial dose as disclosed herein;    -   administering Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, via a titration scheme as disclosed        herein until an optimized dose is administered; and    -   prescribing or administering the optimized dose twice daily to        the patient for a time sufficient to produce a difference of at        least about 45 meters in 6MWD by tire patient relative to the        6MWD prior to administration of the initial dose.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising

-   -   prescribing and/or administering to a patient in need thereof        Compound 1, or a    -   pharmaceutically acceptable salt, hydrate, or solvate thereof,        at an initial dose as disclosed herein;    -   administering Compound 1, or a pharmaceutically acceptable salt,        hydrate, or solvate thereof, via a titration scheme as disclosed        herein until an optimized dose is administered; and    -   prescribing or administering the optimized dose twice daily to        the patient for a time sufficient to produce a difference of at        least about 50 meters in 6MWD by the patient relative to the        6MWD prior to administration of the initial dose.

In some embodiments provided herein is a method of treating pulmonaryarterial hypertension comprising prescribing and/or administering to apatient in need thereof Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, at an initial dose as disclosedherein; and administering Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, via a titration scheme as disclosedherein until an optimized dose is administered, the titration schemecomprises the up-titration of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, over a period of no morethan about nine weeks until the optimized dose is administered.

Also provided is a titration package for enabling compliance with aregimen of changing dosage of medication over a period of time, whereinthe medication is Compound 1, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, the package comprising:

-   -   a backing having an array of receivers, said array including a        plurality of columns aid a plurality of rows;    -   a plurality of sets of solid dosage forms, each solid dosage        form in a set having a common dose of the medication and a        different dose than a solid dosage form of a different set, each        set being disposed in receivers of one of an adjacent row and an        adjacent column; different sets of solid dosage forms are        disposed in different rows, each row being indicated as a        successive time period, each column being indicated as a        different day of the time period, sets of solid dosage forms        having increased doses being disposed in receivers of rows        indicated as successive time periods; and indicia disposed        adjacent the columns and rows for displaying common days and        successive time periods.

In some embodiments of the titration package, a plurality of doses of0.01 mg each is disposed in receivers of a first row.

In some embodiments of the titration package, a plurality of doses of0.02 mg each is disposed in receivers of a second row.

In some embodiments of the titration package, a plurality of doses of0.03 mg each is disposed in receivers of a third row.

In some embodiments of the titration package, a plurality of doses of0.04 mg each is disposed in receivers of a fourth row.

In some embodiments of the titration package, a plurality of doses of0.06 mg each is disposed in receivers of a fifth row.

In some embodiments of the titration package, a plurality of doses of0.08 mg each is disposed in receivers of a sixth row.

In some embodiments of the titration package, a plurality of doses of0.1 mg each is disposed in receivers of a seventh row.

In some embodiments of the titration package, a plurality of doses of0.2 mg each is disposed in receivers of an eighth row.

In some embodiments of the titration package, a plurality of doses of0.3 mg each is disposed in receivers of a ninth row.

In some embodiments of the titration package, a plurality of doses of0.6 mg each is disposed in receivers of a tenth row.

In some embodiments of the titration package, a plurality of doses of0.01 mg each is disposed in receivers of a first row.

In some embodiments of the titration package, a plurality of doses of0.01 mg each is disposed in receivers of a second row, wherein thenumber of doses disposed in the receivers of the second row is twice thenumber of doses disposed in the receivers of the second row.

In some embodiments of the titration package, a plurality of doses of0.02 mg each is disposed in receivers of a third row.

In some embodiments of the titration package, a plurality of doses of0.03 mg each is disposed in receivers of a fourth row.

In some embodiments of the titration package, a plurality of doses of0.04 mg each is disposed in receivers of a fifth row.

In some embodiments of the titration package, a plurality of doses of0.06 mg each is disposed in receivers of a sixth row.

In some embodiments of the titration package, a plurality of doses of0.08 mg each is disposed in receivers of a seventh row.

In some embodiments of the titration package, a plurality of doses of0.1 mg each is disposed in receivers of an eighth row.

In some embodiments of the titration package, a plurality of doses of0.2 mg each is disposed in receivers of a ninth row.

In some embodiments of the titration package, a plurality of doses of0.3 mg each is disposed in receivers of a tenth row.

In some embodiments of the titration package, a plurality of doses of0.6 mg each is disposed in receivers of an eleventh row.

In some embodiments of the titration package, each tune period is aboutone week.

Also provided is a method of “combination” therapy comprisingprescribing and/or administering Compound 1, or a pharmaceuticallyacceptable salt, solvate, or hydrate thereof, in combination with atleast one known pharmaceutical agent. Also provided is a method of“combination” therapy comprising prescribing and/or administeringCompound 1, or a pharmaceutically acceptable salt, solvate, or hydratethereof, in combination with at least one known pharmaceutical agent asdescribed herein and a pharmaceutically acceptable carrier. As usedherein, “combination” as used in reference to drug combinations and/orcombinations of Compound 1, or a pharmaceutically acceptable salt,solvate, or hydrate thereof, with at least one additional pharmaceuticalagent refers to (1) a product comprised of two or more components, i.e.,drug/device, biologic/device, drug/biologic, or drug/device/biologic,that are physically, chemically, or otherwise combined or mixed andproduced as a single entity-; (2) two or more separate products packagedtogether in a single package or as a unit and comprised of drug anddevice products, device and biological products, or biological and drugproducts; (3) a drug, device, or biological product packaged separatelythat according to its investigational plan or proposed labeling isintended for use only with an approved individually specified drug,device, or biological product where both are required to achieve theintended use, indication, or effect and where upon approval of theproposed product the labeling of the approved product would need to bechanged, e.g., to reflect a change in intended use, dosage form,strength, route of administration, or significant change in dose; or (4)any investigational drug, device, or biological product packagedseparately that according to its proposed labeling is for use only withanother individually specified investigational drug, device, orbiological product where both are required to achieve the intended use,indication, or effect. Combinations include without limitation afixed-dose combination product (FDC) in which two or more separate drugcomponents are combined in a single dosage form; a co-packaged productcomprising two or more separate drug products in their final dosageforms, packaged together with appropriate labeling to support thecombination use; and an adjunctive therapy in which a patient ismaintained on a second drug product that is used together with (i.e., inadjunct to) the primary treatment, although tire relative doses are notfixed, and the drags or biologics are not necessarily given at the sametime. Adjunctive therapy products may be co-packaged, and may or may notbe labeled for concomitant use.

In some embodiments, Compound 1, or a pharmaceutically acceptable salt,solvate, or hydrate thereof is administered in combination withthrombolytic therapy, for example, tissue-type plasminogen activator(t-PA), to provide cardioprotection following Ml or postischemicmyocardial dysfunction or protection from ischemic injury duringpercutaneous coronary intervention, and the like, includingcomplications resulting therefrom. PGI2 receptor agonists can also beused in antiplatelet therapies in combination with, for example,alpha-tocopherol (vitamin E), echistatin (a disintegrin) or, in statesof hypercoaguability, heparin. (See, e.g., Chan., J. Nutr., 1998,128:1593-1596; Mardla et al. Platelets, 2004, 15:319-324; Bernabei etal., Ann. Thorac. Surg., 1995, 59:149-153; Gainza et al. J. Nephrol.,2006, 19:648-655.)

In some embodiments. Compound 1, or a pharmaceutically acceptable salt,solvate, or hydrate thereof, is administered together with at least onepharmaceutical agent known to prevent and/or treat one or more of theadverse effects described herein.

In some embodiments, the at least one pharmaceutical agent is an agentfor thrombolytic therapy. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and theagent for thrombolytic therapy are formulated as a fixed dosecombination product. In some embodiments. Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and theagent for thrombolytic therapy are formulated as a co-packaged product,in some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, solvate, or hydrate thereof and the agent for thrombolytic therapyare formulated for adjunctive therapy.

In some embodiments, the at least one pharmaceutical agent istissue-type plasminogen activator. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and thetissue-type plasminogen activator are formulated as a fixed dosecombination product. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and thetissue-type plasminogen activator are formulated as a co-packagedproduct. In some embodiments, the Compound 1, or a pharmaceuticallyacceptable salt, solvate, or hydrate thereof and the tissue-typeplasminogen activator are formulated for adjunctive therapy.

In some embodiments, the at least one pharmaceutical agent is an agentfor antiplatelet therapy. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and theagent for antiplatelet therapy are formulated as a fixed dosecombination product. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and theagent for antiplatelet therapy are formulated as a co-packaged product.In some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, solvate, or hydrate thereof and the agent for antiplatelet therapyare formulated for adjunctive therapy.

In some embodiments, the at least one pharmaceutical agent is an agentfor antiplatelet therapy. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and theagent for antiplatelet therapy are formulated as a fixed dosecombination product. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and theagent for antiplatelet therapy are formulated as a co-packaged product.In some embodiments, the Compound 1, or a pharmaceutically acceptablesalt, solvate, or hydrate thereof and the agent for antiplatelet therapyare formulated for adjunctive therapy.

In some embodiments, the at least one pharmaceutical agent isalpha-tocopherol. In some embodiments, Compound 1, or a pharmaceuticallyacceptable salt, solvate, or hydrate thereof and the alpha-tocopherolare formulated as a fixed dose combination product. In some embodiments.

Compound 1, or a pharmaceutically acceptable salt, solvate, or hydratethereof and the alpha-tocopherol are formulated as a co-packagedproduct. In some embodiments, the Compound 1, or a pharmaceuticallyacceptable salt, solvate, or hydrate thereof and the alpha-tocopherolare formulated for adjunctive therapy.

In some embodiments, the at least one pharmaceutical agent isechistatin. In some embodiments, Compound 1, or a pharmaceuticallyacceptable salt, solvate, or hydrate thereof and the echistatin areformulated as a fixed dose combination product. In some embodiments,Compound 1, or a pharmaceutically acceptable salt, solvate, or hydratethereof and the echistatin are formulated as a co-packaged product. Insome embodiments, the Compound 1, or a pharmaceutically acceptable salt,solvate, or hydrate thereof and the echistatin are formulated foradjunctive therapy.

In some embodiments, the at least one pharmaceutical agent is heparin.In some embodiments, Compound 1, or a pharmaceutically acceptable salt,solvate, or hydrate thereof and the heparin are formulated as a fixeddose combination product. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and theheparin are formulated as a co-packaged product. In some embodiments,the Compound 1, or a pharmaceutically acceptable salt, solvate, orhydrate thereof and the heparin me formulated for adjunctive therapy.

In some embodiments, the at least one pharmaceutical agent is at leastone pharmaceutical agent known to prevent and/or treat one or more ofthe adverse effects described herein. In some embodiments. Compound 1,or a pharmaceutically acceptable salt, solvate, or hydrate thereof andthe at least one pharmaceutical agent known to prevent and/or treat oneor more of the adverse effects described herein are formulated as afixed dose combination product. In some embodiments, Compound 1, or apharmaceutically acceptable salt, solvate, or hydrate thereof and the atleast one pharmaceutical agent known to prevent and/or treat one or moreof the adverse effects described herein are formulated as a co-packagedproduct. In some embodiments, the Compound 1, or a pharmaceuticallyacceptable salt, solvate, or hydrate thereof and the at least onepharmaceutical agent known to prevent and/or treat one or more of theadverse effects described herein are formulated for adjunctive therapy.

Also provided is a kit comprising a titration package as disclosedherein and instructions indicating that the medication is to beadministered to a patient in need of treatment of pulmonary arterialhypertension.

Also provided is a method of treating pulmonary arterial hypertensioncomprising providing a titration package as disclosed herein to patientin need thereof.

In some embodiments. Compound 1 or a pharmaceutically acceptable salt,solvate or hydrate thereof is administered in a tablet or a capsulesuitable for oral administration, in some embodiments, Compound 1 or apharmaceutically acceptable salt, solvate or hydrate thereof isadministered in a capsule suitable for oral administration.

Conventional excipients, such as binding agents, fillers, acceptablewetting agents, tabletting lubricants and disintegrants can be used intablets and capsules for oral administration. Liquid preparations fororal administration can be in the form of solutions, emulsions, aqueousor oily suspensions and syrups. Alternatively, the oral preparations canbe in the form of dry powder that can be reconstituted with water oranother suitable liquid vehicle before use. Additional additives such assuspending or emulsifying agents, non-aqueous vehicles (including edibleoils), preservatives and flavorings and colorants can be added to theliquid preparations. Parenteral dosage forms can be prepared bydissolving the compound in a suitable liquid vehicle and filtersterilizing the solution before filling and sealing an appropriate vialor ampule. These are just a few examples of the many appropriate methodswell known in the art for preparing dosage form s. Suitablepharmaceutically-acceptable carriers, outside those mentioned herein,are known in the art; for example, see Remington, The Science andPractice of Pharmacy, 20^(th) Edition, 2000, Lippincott Williams &Wilkins, (Editors: Gennaro et al.)

While it is possible that, for use in the prophylaxis or treatment, acompound can, in an alternative use, be administered as a raw or purechemical, it is preferable however to present the compound or activeingredient as a pharmaceutical formulation or composition furthercomprising a pharmaceutically acceptable carrier.

Pharmaceutical formulations include those suitable for oral, rectal,nasal, topical (including buccal and sub-lingual), vaginal or parenteral(including intramuscular, sub-cutaneous and intravenous) administrationor in a form suitable for administration by inhalation, insufflation orby a transdermal patch. Transdermal patches dispense a drug at acontrolled rate by presenting the drag for absorption in an efficientmanner with minimal degradation of the drag. Typically, transdermalpatches comprise an impermeable backing layer, a single pressuresensitive adhesive and a removable protective layer with a releaseliner. One of ordinary skill in the art wall understand and appreciatethe techniques appropriate for manufacturing a desired efficacioustransdermal patch based upon the needs of the artisan.

The compounds provided herein, together with a conventional adjuvant,carrier, or diluent, can thus be placed into the form of pharmaceuticalformulations and unit dosages thereof and in such form may be employedas solids, such as tablets or filled capsules, or liquids, such assolutions, suspensions, emulsions, elixirs, gels or capsules filled withthe same, all for oral use, in the form of suppositories for rectaladministration; or in the form of sterile injectable solutions forparenteral (including subcutaneous) use. Such pharmaceuticalcompositions and unit dosage forms thereof can comprise conventionalingredients in conventional proportions, with or without additionalactive compounds or principles and such unit dosage forms may containany suitable effective amount of the active ingredient commensurate withthe intended daily dosage range to be employed.

For oral administration, the pharmaceutical composition can be in theform of, for example, a tablet, capsule, suspension or liquid. Thepharmaceutical composition is preferably made in the form of a dosageunit containing a particular amount of the active ingredient. Examplesof such dosage units are capsules, tablets, powders, granules or asuspension, with conventional additives such as lactose, mannitol, cornstarch or potato starch; with binders such as crystalline cellulose,cellulose derivatives, acacia, corn starch or gelatins; withdisintegrators such as corn starch, potato starch or sodiumcarboxymethyl-cellulose; and with lubricants such as talc or magnesiumstearate. Tire active ingredient may also be administered by injectionas a composition wherein, for example, saline, dextrose or water may beused as a suitable pharmaceutically acceptable carrier.

The compounds provided herein can be administrated in a wide variety oforal and parenteral dosage forms. It will be obvious to those skilled inthe art that the dosage forms may comprise, as the active component,either a compound provided herein or a pharmaceutically acceptable salt,solvate or hydrate of a compound provided herein.

Some embodiments include a method of producing a pharmaceuticalcomposition for “combination-therapy” comprising admixing at least onecompound according to any of the compound embodiments disclosed herein,together with at least one known pharmaceutical agent as describedherein and a pharmaceutically acceptable carrier.

Further embodiments include the embodiment disclosed in the followingExample, which is not to be construed as limiting in any way.

Example 1—Single Ascending Dose Study with Healthy Subjects

This study was a phase 1, randomized, double-blind, placebo-controlledstudy of four cohorts of 8 subjects each (2 subjects were assigned toreceive placebo, and 6 to receive Compound 1). Each cohort was assignedto receive a single dose level of blinded study medication in anascending dose fashion; dosing began at 0.1 mg.

All enrolled subjects received a single oral dose of study medication(Compound 1 or placebo). Dose escalation was slowed or discontinued whenpredefined safety criteria based on peak plasma exposure levels, bloodpressure changes, or adverse events (AEs) were met. Dose escalation wasdiscontinued based on AEs of prolonged nausea and vomiting that wassevere in intensity experienced by subjects during the 2nd cohort (0.2mg Compound 1). Two lower dose cohorts were added, in which the doses ofCompound 1 were 0.05 mg and 0.03 respectively.

After each cohort was dosed, the following safety parameters weremonitored: vital signs, clinical laboratory tests to include serumchemistry, hematology, and urinalysis, 12-lead ECG, plasma Compound 1concentration, and AEs. Pharmacokinetic parameters-were monitored andcalculated for Compound 1.

Adverse Events

A summary of the adverse events observed in tins study is shown in table1.

TABLE 1 a) Summary of adverse events Placebo 0.03 mg 0.05 mg 0.1 mg 0.2mg No. of subjects 8 6 6 6 6 No. of subjects 3 2 5 6 6 reporting AEsPhotophobia 0 0 1 0 0 Nausea 0 0 1 2 3 Vomiting 0 0 0 2 6 Abdominal 0 01 1 0 pain Diarrhoea 0 0 0 0 1 Jaw pain 0 0 2 3 1 Neck pain 0 0 0 1 0Muscle spasm 0 0 0 0 1 Pain in 0 0 0 0 1 extremity Headache 3 2 5 5 5Dizziness 0 0 0 1 0 Cough 1 0 0 0 0 Oropharyngeal 0 0 0 0 1 painFlushing 0 0 1 1 2 At each level of summarization in Table 1a), subjectsreporting more than one event were only counted once b) Number ofSubjects Reporting AEs By Most Direct Relationship to Study TreatmentPlacebo 0.03 mg 0.05 mg 0.1 mg 0.2 mg Probably 0 0 0 1 6 relatedPossibly 1 2 5 4 0 related Probably not 0 0 0 0 0 related Definitely not2 0 0 1 0 related

Example 2—Multiple Ascending Dose Study with Healthy Subjects

This study was a phase 1, randomized, double-blind, placebo-controlled,multiple-dose, dose titration study. A titration interval of 6 days wasemployed, with each dose being administered for at least 5 days. Onegoal was to determine the effect of dose titration on adverse effects.

In each of two subject cohorts, Cohort 1 aid Cohort 2, subjects weretreated at each dose level for duration of 5 days with exception of thelast dose level which included 7 days of treatment.

The protocol was amended to provide for an additional cohort, Cohort 3,in order to evaluate a different dose escalation regimen, as disclosedbelow.

Cohorts 1 and 2: Two groups of 15 subjects were enrolled and randomizedto receive placebo (5 subjects per Cohort) or a starting dose of 0.05 mgCompound 1 (10 subjects per Cohort) on Day 1. Once daily (q.d.) dosingcontinued through 5 days. If tolerated, the next dose escalation(placebo or 0.1 mg q.d. Compound 1) occurred on Day 6 and this dose wasadministered daily through Day 10. Subsequent dose escalations were tooccur in the same manner every 6th day for up to 3 additional doseescalations if tolerated (placebo or 0.2, 0.3, and 0.4 mg Compound 1)with the final dose maintained for a duration of 7 days. The dose couldbe decreased (“de-escalated”) or increased (“re-escalated”) based onassessment of safety and tolerability.

Cohort 3: One group of 25 subjects (5 placebo and 20 active) wereenrolled and randomized to receive a starting dose of 0.01 mg Compound 1twice daily or placebo on Day 1. Twice daily dosing continued through 5days. If tolerated, the next dose escalation (placebo or Compound 1 0.02mg twice daily) occurred on Day 6 and this dose was administered dailythrough Day 10. Subsequent dose escalations were to occur in the samemanner every 6th day for up to 4 additional dose escalations iftolerated (placebo or 0.03, 0.04, 0.05, and 0.07 mg twice daily Compound1). The dose could be decreased (“de-escalated”) or increased(“re-escalated”) based on assessment of safety and tolerability. Thedoses tested in this cohort were 0.01, 0.02, 0.03, 0.04, 0.05, and 0.07mg administered twice daily for a total daily dose of 0.02, 0.04, 0.06,0.08, 0.1, and 0.14 mg, respectively.

Compound 1 capsules were provided as 0.01 mg (alt Cohorts) and 0.1 mg(Cohorts 1 and 2 only) strengths.

In the single-ascending dose study of Example 1 above, the initialstarting dose of 0.1 mg was tolerated but some subjects experiencednausea, vomiting, headache, and jaw pain. Intolerable AEs wereexperienced at the next dose level of 0.2 mg in that study. Accordingly,the starting dose in Cohorts 1 and 2 in this Example 2 the initial dosewas 0.05 mg.

Adverse Events

In Cohorts 1 and 2, three (15%) subjects were unable to tolerate thestarting dose of 0.05 mg once daily. Of these, 2 subjects werede-escalated to the lowest dose of 0.03 mg once daily for the remainderof the study; 1 of the subjects was able to subsequently re-escalate to0.05 mg for the remainder of the study. One subject withdrew on Day 1 ofthe study One subject was able to escalate to 0.2 mg once daily, but wasthen de-escalated over time to 0.03 mg once daily by the remainder ofthe study. One subject tolerated the 0.2 mg once daily dose, and thissame subject attained the highest dose administered to a study subjectin Cohorts 1 and 2 at 0.4 mg once daily. However, the 0.4 mg once dailydose was not tolerated and the subject finished the remainder of thestudy at the 0.3 mg dose once daily.

In Cohort 3, all of the subjects were able to tolerate the starting doseof 0.01 mg twice daily and the first escalation to 0.02 mg twice dailyCompound 1. Five subjects completed the study at the 0.03 mg twice dailydose. Two subjects were able to escalate to the 0.04 mg twice daily doselevel through study completion. Five subjects were able to escalate tothe 0.05 mg dose level through study completion. Two subjects were ableto escalate to 0.07 mg twice daily, the highest dose level administeredto a study subject in Cohort 3. This dose was tolerated through studycompletion. One subject discontinued treatment on Day 2.0 due to anadverse event.

For each cohort, the final daily dose of Compound 1 taken by subjectswas as shown in Table 2 below:

TABLE 2 Final Compound 1 Total Daily Dose mg) Cohorts 1 and 2 Cohort 30.03 mg - 3 subjects 0.04 mg - 4 subjects 0.05 mg - 9 subjects 0.06 mg -6 subjects 0.10 mg - 7 subjects 0.08 mg - 2 subjects 0.30 mg - 1 subject0.10 mg - 6 subjects 0.14 mg - 2 subjects

The highest dose that a subject received for at least 3 days in eitherCohort 1 and 2 or Cohort 3 was as shown in fable 3 below:

TABLE 3 highest dose that a subject received for at least 3 days Cohorts1 and 2 Cohort 3 0.03 mg - 17 subjects 0.04 mg - 20 subjects  0.1 mg - 8subjects 0.04 mg - 20 subjects  0.2 mg - 1 subjects 0.06 mg - 19subjects 0.30 mg - 1 subject 0.08 mg - 11 subjects 0.10 mg - 8 subjects0.14 mg - 3 subjects

A summary of the adverse events leading to a decrease of the dose ofCompound 1 observed in Cohorts 1 and 2 is shown in table 4.

TABLE 4 Adverse Events (no of subjects) leading to Decrease of Compound1 Dose in Cohorts 1 and 2 Total (all Placebo doses) 0.03 mg 0.05 mg 0.1mg 0.2 mg 0.3 mg 0.4 mg (N = 10) (N = 20) (N = 4) (N = 20) (N = 16) (N =5) (N = 1) (N = 1) Vomiting 0 8 0 4 2 2 0 0 Headache 0 8 0 2 5 1 0 0Nausea 0 4 0 1 1 2 0 0 Diarrhoea 0 1 0 1 0 0 0 0 Chest pain 0 1 0 0 1 00 0 Jaw pain 0 1 0 0 1 0 0 0 Erythema 0 1 0 0 0 0 0 1 At each level ofsummarization in Table 1a), subjects reporting more than one event wereonly counted once

A summary of the adverse events leading to a decrease of the dose ofCompound 1 observed in Cohort 3 is shown in table 5.

TABLE 5 Adverse Events (no. of subjects) leading to Decrease of Compound1 Dose in Cohort 3 Total (all Placebo doses) 0.01 mg 0.02 mg 0.03 mg0.04 mg 0.05 mg 0.07 mg (N = 5) (N = 20) (N = 20) (N = 20) (N = 20) (N =12) (N = 8) (N = 4) Headache 0 10 1 6 1 1 0 1 Nausea 0 5 0 3 1 0 0 1Myalgia 0 4 1 2 1 0 0 0 Dizziness 0 3 0 0 0 2 1 0 Abdominal pain 0 2 0 01 0 1 0 Diarrhoea 0 2 0 1 1 0 0 0 Arthralgia 1 2 0 1 0 0 0 1 Chestdiscomfort 0 1 0 0 1 0 0 0 Chest pain 0 1 0 1 0 0 0 0 Palpitations 0 1 01 0 0 0 0 Vomiting 0 1 0 1 0 0 0 0 Priapism 0 1 0 0 1 0 0 0 Jaw pain 0 10 0 0 0 0 1The majority of subjects, regardless of treatment group, experienced oneor more APIs, Most of the AEs reported in the study were consideredmoderate in intensity (88%). Within the Compound 1 group, 95% of AEswere considered moderate in intensity and 90% were deemed by theinvestigator to be probably related to study drug.

Example 3—Administration of Compound 1 to Patients

A capsule containing an initial dose of 0.01 mg of Compound 1 isadministered to a patient twice daily for one week. Tire patient is thenevaluated by a health care practitioner to determine whether the patienttolerates the initial dose. If the patient does not tolerate the 0.01 mginitial dose, Compound 1 is not administered to the patient further. Ifthe patient tolerates the initial dose, the dose is increased to 0.02mg. A capsule containing tire increased dose of 0.02 mg of Compound 1 isadministered to a patient twice daily for one week and the patient isagain evaluated to determine whether the patient tolerates the dose. Thecycle is repeated, further increasing the dose, according to thefollowing schedule, provided that the patient continues to tolerate theincreased or further increased, dose.

TABLE 6 Amount of Compound 1 (in mg) administered to the patient duringeach of nine weeks Week Week Week Week Week Week Week Week Week 1 2 3 45 6 7 8 9 Dose 0.01 Increased 0.02 Dose Further 0.03 0.04 0.06 0.08 0.10.2 0.3 Increased Dose

If a dose is reached where the patient does not tolerate that dose,Compound 1 is not administered to the patient further. The optimizeddose for that patient is the highest dose tolerated by that patient. Asan example, a patient is administered 0.01 mg of Compound 1 twice dailyon Week 1, 0.02 mg of Compound 1 twice daily on Week 2, 0.03 mg ofCompound 1 twice daily on Week 3, and 0.04 mg of Compound 1 twice dailyon Week 4, each time tolerating tire dose. The patient is administered0.06 mg of Compound 1 twice daily on Week 5, and does not tolerate the0.06 mg twice daily. The optimized dose for the patient is 0.04 mg ofCompound 1 twice daily.

Example 4—Administration of Compound 1 to Patients

This study is conducted as a 22 week, randomized, double-blind, placebocontrolled study which includes a dose titration period of up to 9weeks. Patients are randomized 2:1 active to placebo.

Right Heart Catheterization (RHC) measurements are obtained prior tostudy Day 1 of the dose titration period and at Week 22. The followingvalues are obtained and recorded: PAP (systolic, diastolic, and mean),HR, right atrial pressure (RAP), pulmonary capillary wedge pressure(PCWP) right ventricular pressure (RVP) and cardiac output (CO),pulmonary vascular resistance (PVR), arterial and mixed venous oxygensaturation, FiO2 (if applicable). Systemic vascular resistance (SVR) isestimated from blood pressure measurements.

The primary efficacy endpoints are: a) change from baseline in PVR after22 weeks of treatment, and b) change from baseline in 6 MWD after 22weeks of treatment. Efficacy is assessed in a stepwise manner: thestatistical significance of Compound 1 versus placebo result isdetermined for the change from baseline in PVR at the end of 22 weeks oftreatment. If the change from baseline in PVR is significant (p<0.05,two-sided), the change from baseline in 6MWD is then tested.

Compound 1 is administered as a hard-gelatin capsule formulation in0.01, 0.02, 0.03, 0.04, and 0.10 mg dose strengths.

The starting dose of Compound 1 is 0.01 mg twice daily. The dose ofCompound 1 is titrated according to patient tolerability. Availabledosage forms include 0.01, 0.02, 0.03, 0.04 mg, and 0.10 mg.

If the initial dose is tolerated (0.01 mg twice daily), then the dose isincreased once a week in the following fashion: 0.02 mg twice daily,0.03 mg twice daily, 0.04 mg twice daily, 0.06 mg twice daily, 0.08 mg,0.1 mg twice daily, 0.2 mg twice daily and 0.3 mg twice daily. The dosemay be escalated to a possible maximum total daily dose of 0.6 mg (0.3mg twice daily) pending tolerability.

If a dose is not tolerated, the study drug may be decreased to theprevious dose level. If the initial dose of 0.01 mg twice daily is nottolerated, dosing may be decreased to 0.01 mg once daily.

In this example, the 6MWD is determined according to the followingSix-minute Walk Test (“6MWT”):

The 6MWT is performed indoors along a long, flat, straight, hallway witha hard surface 15-50 meters in length having a preset starting line andturnaround points. If more than one test is performed, repeat testing isperformed about the same time of day. Prior to the test the lap counteris set to 0 and the time to 6 minutes. The subject is instructed to walkas far as possible for 6 minutes by walking back and forth in thehallway, without running or jogging. The subject is instructed not totalk during the walk. The subject is notified at one-minute intervals ofthe time remaining in the 6MWT—thus, for example, the subject isnotified after the first minute that there me five minutes remaining.When there are 15 seconds from completion of the 6MWT, the subject isnotified that the subject is about to be told to stop walking. At thesix-minute mark, as indicated (for example) by a buzzer, the subject istold to stop walking and the spot where the subject has stopped ismarked with tape. The number of laps is recorded, and the number ofmeters in the final partial lap is recorded using a tape measure. Thetotal distance walked is calculated, rounding to the nearest meter, andrecorded.

Other uses of the disclosed methods will become apparent to those in theart based upon, inter alia, a review of this patent document.

What is claimed is:
 1. A titration package for enabling compliance witha regimen of changing dosage of medication over a period of time,wherein the medication is2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbarnoyloxy)methyl)cyclohexyl)methoxy)aceticacid (Compound 1), or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, the package comprising: a backing having an array ofreceivers, said array including a plurality of columns and a pluralityof rows; a plurality of sets of solid dosage forms, each solid dosageform in a set having a common dose of the medication and a differentdose than a solid dosage form of a different set, each set beingdisposed in receivers of one of an adjacent row and an adjacent column;different sets of solid dosage forms are disposed in different rows,each row being indicated as a successive time period, each column beingindicated as a different day of the time period, sets of solid dosageforms having increased doses being disposed in receivers of rowsindicated as successive time periods; and indicia disposed adjacent thecolumns and rows for displaying common days and successive time periods.2. A kit comprising a titration package of claim 1 and instructionsindicating that the medication is to be administered to a patient inneed of treatment of pulmonary arterial hypertension.
 3. A method oftreating pulmonary arterial hypertension comprising providing a kit ofclaim 2 to patient in need thereof.
 4. The titration package of claim 1,wherein the plurality of sets of solid dosage forms comprise one or moreof the following sets: a set of solid dosage forms comprising an amountof Compound 1, or a pharmaceutically acceptable salt, hydrate, orsolvate thereof, equivalent to 0.01 mg of Compound 1; a set of soliddosage forms comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.02 mg ofCompound 1; a set of solid dosage forms comprising an amount of Compound1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.03 mg of Compound 1; a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.04 mg of Compound 1;a set of solid dosage forms comprising an amount of Compound 1 or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.06 mg of Compound 1; a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.08 mg of Compound 1;a set of solid dosage forms comprising an amount of Compound 1 or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.1 mg of Compound 1; a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.2 mg of Compound 1; aset of solid dosage forms comprising an amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.3 mg of Compound 1; and a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.6 mg of Compound 1.5. The titration package of claim 1, wherein the plurality of sets ofsolid dosage forms comprise an initial set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.05 mg of Compound 1once daily in each receiver of the first row.
 6. The titration packageof claim 5, wherein the plurality of sets of solid dosage forms comprisea second set of solid dosage forms comprising an amount of Compound 1,or a pharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.1 mg of Compound 1 once daily in each receiver of thesecond row.
 7. The titration package of claim 5, wherein the amount ofCompound 1, or a pharmaceutically acceptable salt, hydrate, or solvatethereof, increases by an amount equivalent to 0.05 mg of Compound 1 ineach successive row.
 8. The titration package of claim 1, wherein theplurality of sets of solid dosage forms comprise an initial set of soliddosage forms comprising 0.05 mg of Compound 1 once daily in eachreceiver of the first row.
 9. The titration package of claim 8, whereinthe plurality of sets of solid dosage forms comprise a second set ofsolid dosage forms comprising 0.1 mg of Compound 1 once daily in eachreceiver of the second row.
 10. The titration package of claim 8,wherein the amount of Compound 1 increases by 0.05 mg of Compound 1 ineach successive row.
 11. The titration package of claim 8, wherein theinitial set of solid dosage forms are configured to be administered forabout a week, and each time period is about one week.
 12. The kit ofclaim 2, wherein the plurality of sets of solid dosage forms compriseone or more of the following sets: a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.01 mg of Compound 1;a set of solid dosage forms comprising an amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.02 mg of Compound 1; a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.03 mg of Compound 1;a set of solid dosage forms comprising an amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.04 mg of Compound 1; a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.06 mg of Compound 1;a set of solid dosage forms comprising an amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.08 mg of Compound 1; a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.1 mg of Compound 1; aset of solid dosage forms comprising an amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.2 mg of Compound 1; a set of solid dosage formscomprising an amount of Compound 1, or a pharmaceutically acceptablesalt, hydrate, or solvate thereof, equivalent to 0.3 mg of Compound 1;and a set of solid dosage forms comprising an amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.6 mg of Compound
 1. 13. The kit of claim 2, wherein theplurality of sets of solid dosage forms comprise an initial set of soliddosage forms comprising an amount of Compound 1, or a pharmaceuticallyacceptable salt, hydrate, or solvate thereof, equivalent to 0.05 mg ofCompound 1 once daily in each receiver.
 14. The kit of claim 13, whereinthe plurality of sets of solid dosage forms comprise a second set ofsolid dosage forms comprising an amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof,equivalent to 0.1 mg of Compound 1 once daily in each receiver.
 15. Thetitration package of claim 13, wherein the amount of Compound 1, or apharmaceutically acceptable salt, hydrate, or solvate thereof, increasesby an amount equivalent to 0.05 mg of Compound 1 in each successive row.16. The kit of claim 2, wherein the plurality of sets of solid dosageforms comprise an initial set of solid dosage forms comprising 0.05 mgof Compound 1 once daily in each receiver.
 17. The kit of claim 16,wherein the plurality of sets of solid dosage forms comprise a secondset of solid dosage forms comprising 0.1 mg of Compound 1 once daily ineach receiver.
 18. The kit of claim 16, wherein the amount of Compound 1increases by 0.05 mg of Compound 1 in each successive row.
 19. The kitof claim 2, wherein the initial set of solid dosage forms are configuredto be administered for about a week, and each time period is about oneweek.
 20. The kit of claim 2, wherein the pulmonary arterialhypertension (PAH) is selected from: idiopathic PAH; familial PAH; PAHassociated with a collagen vascular disease selected from: scleroderma,CREST syndrome, systemic lupus erythematosus (SLE), rheumatoidarthritis, Takayasu's arteritis, polymyositis, and dermatomyositis; PAHassociated with a congenital heart disease selected from: atrial septicdefect (ASD), ventricular septic defect (VSD) and patent ductusarteriosus in a patient; PAH associated with portal hypertension; PAHassociated with HIV infection; PAH associated with ingestion of a drugor toxin; PAH associated with hereditary hemorrhagic telangiectasia; PAHassociated with splenectomy; PAH associated with significant venous orcapillary involvement; PAH associated with pulmonary veno-occlusivedisease (PVOD); and PAH associated with pulmonary capillaryhemangiomatosis (PCH) in a patient.
 21. The kit of claim 2, wherein thepulmonary arterial hypertension (PAH) is selected from: idiopathic PAH;familial PAH; PAH associated with a collagen vascular disease selectedfrom: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE),rheumatoid arthritis, Takayasu's arteritis, polymyositis, anddermatomyositis; and PAH associated with a congenital heart diseaseselected from: atrial septic defect (ASD), ventricular septic defect(VSD) and patent ductus arteriosus in a patient.
 22. The kit of claim 2,wherein the pulmonary arterial hypertension (PAH) is selected fromidiopathic PAH and familial PAH.